Homepage
Author:
Dyne Therapeutics, Inc.
Posted Date:
April 1, 2026
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
Dyne Therapeutics, Inc.
April 1, 2026
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
Dyne Therapeutics, Inc.
March 8, 2026
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics, Inc.
March 8, 2026
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Dyne Therapeutics, Inc.
March 2, 2026
Dyne Therapeutics to Participate in Upcoming Investor Conferences
Dyne Therapeutics, Inc.
February 25, 2026
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
Dyne Therapeutics, Inc.
February 22, 2026
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
Dyne Therapeutics, Inc.
January 26, 2026
